Suppurative periapical periodontitis
disease diseaseOn this page
Also known as dentoalveolar abscessperiapical dental abscess
Summary
Suppurative periapical periodontitis (MONDO:0006989) is a disease with 1 GWAS associations across 6 studies and 2 clinical trials. Top therapeutic interventions include amoxicillin. A subtype of periapical periodontitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 1
- Clinical trials: 2
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | suppurative periapical periodontitis |
| Mondo ID | MONDO:0006989 |
| EFO | EFO:1001202 |
| MeSH | D010482 |
| DOID | DOID:2562 |
| NCIT | C34913 |
| UMLS | C0031024 |
| MedGen | 10652 |
| Is cancer (heuristic) | no |
Also known as: dentoalveolar abscess · periapical dental abscess
Data availability: 1 GWAS association (6 studies).
Disease family
This is a subtype of periapical periodontitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › periodontal disorder › periodontitis › periapical periodontitis › suppurative periapical periodontitis
Related subtypes (3): chronic apical periodontitis, acute apical periodontitis, periapical granuloma
Genetics & variants
GWAS landscape
1 GWAS associations across 6 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs537666179 | 5e-08 | NECTIN3 - CD96 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90478248 | Verma A | 2024 | 5,636 | 431,772 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90478247 | Verma A | 2024 | 2,587 | 112,345 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480859 | Verma A | 2024 | 2,587 | 112,345 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90436266 | Zhou W | 2018 | 1,177 | 398,136 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90478246 | Verma A | 2024 | 999 | 56,668 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90651735 | Liu TY | 2025 | 679 | 208,919 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intergenic_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs537666179 | 3 | 111277968 | AG>A | intergenic_variant | NECTIN3 - CD96 | 5e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 2.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03761264 | PHASE2 | COMPLETED | Systemic and Local Antimicrobials in the Management of Dental Abscess in Children |
| NCT04684407 | Not specified | UNKNOWN | C-reactive Protein Levels in Acute Apical Abscess Due to Root Canal Infection |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| AMOXICILLIN | 4 | 1 |
Related Atlas pages
- Drugs: Amoxicillin